Published in MMWR Morb Mortal Wkly Rep on July 05, 2002
Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol (2003) 16.45
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev (2010) 9.82
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest (2003) 5.33
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 4.22
Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ (2004) 3.86
Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother (2007) 3.54
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol (2006) 3.34
Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 3.33
Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother (2003) 2.80
Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect Immun (2003) 2.59
Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem. Proc Natl Acad Sci U S A (2004) 2.57
Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2006) 2.51
Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis (2006) 2.51
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44
Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother (2005) 2.34
Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in Staphylococcus aureus. J Clin Microbiol (2003) 2.32
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2006) 2.05
Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan. Antimicrob Agents Chemother (2007) 2.01
Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci (2012) 1.91
A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother (2005) 1.88
Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics (2006) 1.86
Coagulase-negative staphylococci. Clin Microbiol Rev (2014) 1.85
Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis (2011) 1.83
Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother (2005) 1.81
MRSA virulence and spread. Cell Microbiol (2012) 1.79
High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother (2006) 1.77
Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol (2008) 1.72
Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun (2003) 1.67
Vancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus. Biochemistry (2008) 1.53
Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol (2008) 1.49
Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2004) 1.48
Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother (2003) 1.48
In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob Agents Chemother (2004) 1.43
Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis (2003) 1.43
Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients. J Glob Infect Dis (2010) 1.42
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother (2005) 1.38
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. J Clin Microbiol (2003) 1.37
Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother (2009) 1.35
Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother (2003) 1.35
Community-associated methicillin-resistant Staphylococcus aureus: trends in case and isolate characteristics from six years of prospective surveillance. Public Health Rep (2009) 1.35
FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci. Antimicrob Agents Chemother (2003) 1.33
Prevalence and antimicrobial resistance of enterococcus species isolated from retail meats. Appl Environ Microbiol (2003) 1.32
Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin. Antimicrob Agents Chemother (2003) 1.31
Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells. Antimicrob Agents Chemother (2005) 1.31
Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother (2008) 1.31
First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J Clin Microbiol (2005) 1.30
The beta-lactam-resistance modifier (-)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology (2007) 1.30
Accuracy and potential usefulness of triplex real-time PCR for improving antibiotic treatment of patients with blood cultures showing clustered gram-positive cocci on direct smears. J Clin Microbiol (2008) 1.29
Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.28
Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother (2005) 1.25
Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.25
[S2 Guideline for diagnosis and therapy of infectious endocarditis]. Z Kardiol (2004) 1.24
Transcription of the Staphylococcus aureus cid and lrg murein hydrolase regulators is affected by sigma factor B. J Bacteriol (2004) 1.23
Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.22
Molecular epidemiology of clinical isolates of methicillin-resistant Staphylococcus aureus in Taiwan. J Clin Microbiol (2004) 1.22
New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis (2008) 1.21
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2003) 1.21
Identification and characterization of sigma, a novel component of the Staphylococcus aureus stress and virulence responses. PLoS One (2008) 1.19
Regulation of the expression of cell wall stress stimulon member gene msrA1 in methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.18
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur J Clin Microbiol Infect Dis (2005) 1.16
Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol (2003) 1.15
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun (2005) 1.15
Genes contributing to Staphylococcus aureus fitness in abscess- and infection-related ecologies. MBio (2014) 1.15
Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.14
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates. Antimicrob Agents Chemother (2004) 1.13
Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol (2003) 1.13
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis (2003) 1.13
Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need. J Clin Microbiol (2004) 1.12
Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother (2004) 1.12
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. Antimicrob Agents Chemother (2013) 1.12
Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother (2004) 1.11
Comparative supragenomic analyses among the pathogens Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae using a modification of the finite supragenome model. BMC Genomics (2011) 1.11
Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg (2008) 1.11
Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran. J Res Pharm Pract (2016) 1.10
Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun (2008) 1.10
Transferable vanB2 Tn5382-containing elements in fecal streptococcal strains from veal calves. Antimicrob Agents Chemother (2003) 1.09
Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother (2005) 1.09
Antimicrobial resistance takes another step forward. CMAJ (2002) 1.08
Molecular epidemiology of clinical and carrier strains of methicillin resistant Staphylococcus aureus (MRSA) in the hospital settings of north India. Ann Clin Microbiol Antimicrob (2006) 1.07
Nosocomial infection with vancomycin-dependent enterococci. Emerg Infect Dis (2004) 1.07
Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother (2006) 1.06
Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City during a 7-year period (1997 to 2003): clonal evolution and impact of infection control. J Clin Microbiol (2004) 1.05
Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother (2004) 1.04
In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother (2004) 1.03
Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides. Int J Mol Sci (2014) 1.03
Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother (2006) 1.03
Treatment guidelines for dialysis catheter-related bacteremia: an update. Am J Kidney Dis (2009) 1.03
Requirement of Staphylococcus aureus ATP-binding cassette-ATPase FhuC for iron-restricted growth and evidence that it functions with more than one iron transporter. J Bacteriol (2006) 1.03
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag (2008) 1.01
Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis (2003) 1.01
Identification and Characterization of a High Vancomycin-Resistant Staphylococcus aureus Harboring VanA Gene Cluster Isolated from Diabetic Foot Ulcer. Iran J Basic Med Sci (2012) 1.00
Survey of methicillin-resistant Staphylococcus aureus strains from two hospitals in El Paso, Texas. J Clin Microbiol (2005) 1.00
Methicillin-resistant Staphylococcus aureus, Hawaii, 2000-2002. Emerg Infect Dis (2005) 0.99
Alkyl gallates, intensifiers of beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 0.99
Threat of drug resistant Staphylococcus aureus to health in Nepal. BMC Infect Dis (2014) 0.99
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep (2006) 37.28
Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 17.76
Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep (2010) 14.85
Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. MMWR Morb Mortal Wkly Rep (2008) 13.54
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 13.20
Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ (2012) 11.57
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ (2014) 11.24
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep (2009) 9.94
Outbreak of West Nile-like viral encephalitis--New York, 1999. MMWR Morb Mortal Wkly Rep (1999) 9.67
Youth risk behavior surveillance - United States, 2009. MMWR Surveill Summ (2010) 9.63
Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003. MMWR Morb Mortal Wkly Rep (2003) 9.37
Youth risk behavior surveillance--United States, 2007. MMWR Surveill Summ (2008) 9.04
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep (2008) 9.02
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep (2011) 8.80
Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep (1999) 8.67
Cigarette smoking among adults--United States, 2004. MMWR Morb Mortal Wkly Rep (2005) 8.60
Vital signs: current cigarette smoking among adults aged ≥18 years--United States, 2005-2010. MMWR Morb Mortal Wkly Rep (2011) 8.45
Annual smoking-attributable mortality, years of potential life lost, and economic costs--United States, 1995-1999. MMWR Morb Mortal Wkly Rep (2002) 8.37
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep (2007) 8.14
Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001. MMWR Morb Mortal Wkly Rep (2005) 8.10
Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 8.03
Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep (2006) 7.90
HIV prevalence estimates--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 7.76
Cigarette smoking among adults--United States, 2000. MMWR Morb Mortal Wkly Rep (2002) 7.32
Notes from the field: electronic cigarette use among middle and high school students - United States, 2011-2012. MMWR Morb Mortal Wkly Rep (2013) 7.28
HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men--five U.S. cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep (2005) 7.25
Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep (1995) 7.11
Quitting smoking among adults--United States, 2001-2010. MMWR Morb Mortal Wkly Rep (2011) 7.06
Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep (2010) 7.04
Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ (2009) 7.02
Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep (2011) 6.90
Cigarette smoking among adults--United States, 2007. MMWR Morb Mortal Wkly Rep (2008) 6.82
Vital signs: current cigarette smoking among adults aged >or=18 years --- United States, 2009. MMWR Morb Mortal Wkly Rep (2010) 6.72
Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep (1999) 6.57
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep (2001) 6.49
Prevalence and awareness of HIV infection among men who have sex with men --- 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep (2010) 6.25
Youth risk behavior surveillance--United States, 2013. MMWR Surveill Summ (2014) 6.17
Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 6.09
Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep (2009) 6.08
Tobacco use among middle and high school students - United States, 2011-2014. MMWR Morb Mortal Wkly Rep (2015) 6.05
National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ (2007) 6.05
Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep (2009) 6.04
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02
CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep (2012) 5.77
Cluster of severe acute respiratory syndrome cases among protected health-care workers--Toronto, Canada, April 2003. MMWR Morb Mortal Wkly Rep (2003) 5.50
Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2011) 5.48
Trends in the prevalence and incidence of self-reported diabetes mellitus -- United States, 1980-1994. MMWR Morb Mortal Wkly Rep (1997) 5.45
Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ (2005) 5.40
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep (1997) 5.30
Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep (2009) 5.29
Severe acute respiratory syndrome--Singapore, 2003. MMWR Morb Mortal Wkly Rep (2003) 5.28
Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep (2009) 5.25
Tobacco use among adults--United States, 2005. MMWR Morb Mortal Wkly Rep (2006) 5.24
Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors--United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003-April 2005. MMWR Surveill Summ (2006) 5.15
Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morb Mortal Wkly Rep (2001) 5.14
Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep (2012) 5.12
Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. MMWR Morb Mortal Wkly Rep (2009) 5.10
Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep (2001) 4.95
Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep (2009) 4.86
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep (1993) 4.77
Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ (2008) 4.77
Barriers to children walking and biking to school--United States, 1999. MMWR Morb Mortal Wkly Rep (2002) 4.76
Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep (2011) 4.68
Subpopulation estimates from the HIV incidence surveillance system--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 4.68
Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep (2014) 4.67
Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep (2012) 4.64
Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep (2008) 4.64
Estimating the future number of cases in the Ebola epidemic--Liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ (2014) 4.53
Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 2009. MMWR Morb Mortal Wkly Rep (2009) 4.50
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2014) 4.50
Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep (2009) 4.48
Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep (2012) 4.45
Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb Mortal Wkly Rep (2014) 4.39
Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep (2005) 4.39
Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep (2005) 4.36
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep (2009) 4.36
Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep (2009) 4.36
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep (2010) 4.34
HIV surveillance--United States, 1981-2008. MMWR Morb Mortal Wkly Rep (2011) 4.30
Forward: CDC Health Disparities and Inequalities Report - United States, 2011. MMWR Surveill Summ (2011) 4.29
Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep (2010) 4.24
Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep (2013) 4.22
National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep (2011) 4.18
Trends in aging--United States and worldwide. MMWR Morb Mortal Wkly Rep (2003) 4.16
Racial/ethnic disparities in diagnoses of HIV/AIDS--33 states, 2001-2005. MMWR Morb Mortal Wkly Rep (2007) 4.16
Methicillin-resistant staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep (2003) 4.14
Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep (2012) 4.13
Ebola virus disease outbreak - Nigeria, July-September 2014. MMWR Morb Mortal Wkly Rep (2014) 4.08
Global youth tobacco surveillance, 2000-2007. MMWR Surveill Summ (2008) 3.98
Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep (2011) 3.98
Impact of an innovative approach to prevent mother-to-child transmission of HIV--Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep (2013) 3.96
Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep (2003) 3.95
Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep (2002) 3.95
Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001--2009. MMWR Morb Mortal Wkly Rep (2011) 3.92
Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep (2010) 3.83